Viridian Therapeutics Q3'26 earnings preview: EPS estimate at $(1.02)
The company is scheduled to report Q3'26 results on November 4 before the market opens. EPS is estimated at $(1.02).
Related stories
Lacroix Group Schedules 2026 Annual Revenue Release
Lacroix Group will release its 2026 annual revenue.
M impact | EQUITY | Nov 03, 2026, 04:40 PM UTC
Lacroix Group Launches Share Buyback Program of Up to €28.97 Million
Lacroix Group launched a share buyback program of up to €28.97 million.
L impact | EQUITY | Nov 03, 2026, 04:40 PM UTC
Lacroix Group Announces Annual 2026 Revenue Publication
Lacroix Group says it will publish its annual 2026 revenue. The publication timing is not provided.
M impact | EQUITY | Nov 03, 2026, 04:40 PM UTC
Lacroix Group Launches Share Buyback Program for Up to 10% of Capital
Lacroix Group has launched a share buyback program covering up to 10% of its capital.
M impact | EQUITY | Nov 03, 2026, 04:40 PM UTC
Neurocrine Biosciences Reports Strong Q3 Results, RBC Says
RBC described Neurocrine Biosciences' Q3 results as strong.
M impact | EQUITY | Nov 03, 2026, 04:39 PM UTC
US API Gasoline Stock Change
L impact | EQUITY | Nov 03, 2026, 04:38 PM UTC